Worldwide Clinical Trials appoints Evelyn Graham

To lead sales, marketing and business development for late-stage business

Worldwide Clinical Trials, a US-based global contract research organisation, has appointed Evelyn Graham as executive vice president, Global Business Development.

With more than 20 years of drug development experience, Graham will lead sales, marketing and business development strategies for the late stage business.

Graham was formerly chief executive of TorreyPines Therapeutics and led the company’s merger with Raptor Pharmaceuticals in September 2009.

You may also like

Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Manufacturing

Anton Paar expands Litesizer DIA Series with new models

Introducing affordable and advanced solutions for particle analysis
Manufacturing

Triple your efficiency with the new DrySyn Vortex

Boost productivity with temperature-controlled parallel reactions
Manufacturing

Five critical design elements for Pelton wheel turbine flowmeters

Titan Enterprises outlines the factors for cost-effective and reliable low-flow measurement
Research & Development

Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics

Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
Manufacturing

Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company

The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
Research & Development

Steritas and argenx join forces to advance steroid-sparing therapeutic development

With the help of Steritas' STOX Suite, argenx aims to develop antibody-based therapeutics for immune diseases, potentially allowing patients to move away from chronic steroid usage
Subscribe now